A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
Status:
Completed
Trial end date:
2017-04-26
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety, efficacy, and dose-response
relationship of IW-3718 administered orally to participants who have GERD and continue to
experience GERD symptoms while receiving once-daily (QD), standard-dose proton pump
inhibitors (PPIs).